The fourth quarter of 2017 saw a flurry of new drug approvals from the FDA. Here’s a brief overview of agents for primary care that were newly approved or that were granted a new indication.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.